尿路性器悪性腫瘍におけるcirculating immune complexesの検討

Abstract

The present investigation was conducted to examine the efficacy of the circulating immune complexes (CIC) in patients with urogenital cancer. A total of 62 patients including 10 cases of renal cell carcinoma, 7 of renal pelvic and/or ureteral cancer, 35 of bladder cancer, 9 of prostatic cancer and 1 of testicular cancer were examined. Twelve patients with urolithiasis, 11 with chronic nephritis, and 12 healthy volunteers were used as controls. CIC levels of the sera and urine in each case were determined by Clq solid-phase enzyme immunoassay technique developed by Japan Medical Laboratories Co., Ltd. CIC levels of the sera in patients with bladder cancer were significantly higher than those in healthy controls (p<0.05). According to the stage and grade of bladder cancer, CIC levels of the sera in Tla, grade 1 and grade 2 patients were significantly higher than those in healthy controls (p<0.05). CIC levels of the urine in patients with bladder cancer and chronic nephritis were significantly higher than those in healthy controls (p<0.05). According to the stage and grade of bladder cancer, CIC levels of the urine in Tla and grade 2 patients were higher than those in healthy controls (p<0.1). These results indicate that high levels of CIC of the sera and urine were present in patients with low stage and low grade bladder cancer. Further investigatins to analyze a tumor specific antigen and to make an antibody from the sample in patients with bladder cancer will be warranted.